Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Phase 1/2 Unknown 6 enrolled Krystal Biotech, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is an intra-patient comparison of KB105 and placebo-administered Target Areas. The primary objectives of this study are to evaluate safety and Investigator Global Assessment (IGA) scale improvement of topically administered KB105.

Timeline

Start: 2019-08-27
Primary completion: 2022-10
Completion: 2025-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INETAGUGENE GEPERPAVEC	Unknown	—	Topical

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Summary

Timeline

Drugs

Indications